A critical evaluation of a nicotine vaccine within a self-administration behavioral model
Abstract
(S)-Nicotine is a psychostimulant legal drug responsible for causing addiction to tobacco smoking. Tobacco smoking has been irrevocably linked to a number of serious diseases and at present is considered the leading cause of preventable death in the United States. Despite well-documented adverse medical consequences, nicotine addiction has historically been one of the hardest to break. Current therapies have offered limited success and show high rates of relapse, emphasizing the need to engineer alternative therapies to aid nicotine cessation. The current study presents a protein-based immunopharmacotherapy approach for the treatment of nicotine addiction. Immunopharmacotherapy aims to use highly specific antibodies to blunt passage of drug into the brain thus minimizing reinforcing effects on the reward pathways of the central nervous system. Generation of a successful vaccine heavily relies on appropriate optimization of hapten design, immunogenic carrier and adjuvant. Modification of a classical nicotine hapten in conjugation with three distinct carrier proteins allowed for priming of a nicotine vaccine able to elicit significant amounts of nicotine-specific antibodies. Increased self-administration with use of a high drug dose (0.03 mg/kg/infusion; approximately 2 cigarettes in human) was observed in the vaccinated versus control animals suggesting a compensatory pattern and possibly reduced passage of nicotine to the brain. These results support the hypothesis that proper optimization of vaccine formulations could lead to successful nicotine vaccines for human use.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
These results confirm other studies using non-inhalation routes of administration.
“These results confirm other studies using non-inhalation routes of administration [250–252].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [251]
Cites
Danaei, G., Ding, E. L., Mozaffarian, D., Taylor, B., Rehm, J., Murray, C. J. L., & Ezzati, M. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000058 · Cited by 2,860 · see citing works
Heterologous prime-boost vaccination
Lu, S. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.05.016 · Cited by 481 · see citing works
Nicotine and its metabolites. Radioimmunoassays for nicotine and cotinine
Langone, J. J., Gjika, H. B., & Vunakis, H. V. (1973) · Biochemistry · doi:10.1021/bi00748a032 · Cited by 394 · see citing works
Maurer, P., Jennings, G. T., Willers, J., Rohner, F., Lindman, Y., Roubicek, K., Renner, W. A., Müller, P., & Bachmann, M. F. (2005) · European Journal of Immunology · doi:10.1002/eji.200526285 · Cited by 279 · see citing works
George, O., Ghozland, S., Azar, M. R., Cottone, P., Zorrilla, E. P., Parsons, L. H., O'Dell, L. E., Richardson, H. N., & Koob, G. F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707585104 · Cited by 245 · see citing works
Self-citationEfficacy of a therapeutic cocaine vaccine in rodent models
Fox, B. S., Kantak, K. M., Edwards, M. A., Black, K. M., Bollinger, B. K., Botka, A. J., French, T. L., Thompson, T. L., Schad, V. C., Greenstein, J. L., et al. (1996) · Nature Medicine · doi:10.1038/nm1096-1129 · Cited by 220 · see citing works
Suppression of psychoactive effects of cocaine by active immunization
Carrera, M. R. A., Ashley, J. A., Parsons, L. H., Wirsching, P., Koob, G. F., & Janda, K. D. (1995) · Nature · doi:10.1038/378727a0 · Cited by 220 · see citing works
Safety and immunogenicity of a nicotine conjugate vaccine in current smokers
HATSUKAMI, D., RENNARD, S., JORENBY, D., FIORE, M., KOOPMEINERS, J., DEVOS, A., HORWITH, G., & PENTEL, P. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.08.007 · Cited by 194 · see citing works
Pentel, P. R., Malin, D. H., Ennifar, S., Hieda, Y., Keyler, D. E., Lake, J. R., Milstein, J. R., Basham, L., Coy, R., Moon, J. W. D., et al. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00206-3 · Cited by 179 · see citing works
Cocaine vaccines: Antibody protection against relapse in a rat model
Carrera, M. R. A., Ashley, J. A., Zhou, B., Wirsching, P., Koob, G. F., & Janda, K. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.6202 · Cited by 155 · see citing works
Müller, R. (1983) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(83)92046-3 · Cited by 115 · see citing works
A second-generation vaccine protects against the psychoactive effects of cocaine
Carrera, M. R. A., Ashley, J. A., Wirsching, P., Koob, G. F., & Janda, K. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1988 · Cited by 114 · see citing works
Active Immunization against Nicotine Prevents Reinstatement of Nicotine-Seeking Behavior in Rats
Lindblom, N., de Villiers, S. H. L., Kalayanov, G., Gordon, S. L., Johansson, A. M., & Svensson, T. H. (2002) · Respiration · doi:10.1159/000063629 · Cited by 106 · see citing works
Hieda, Y., Keyler, D. E., Ennifar, S., Fattom, A., & Pentel, P. R. (2000) · International Journal of Immunopharmacology · doi:10.1016/s0192-0561(00)00042-4 · Cited by 97 · see citing works
Active Immunization Alters the Plasma Nicotine Concentration in Rats
Hieda, Y., Keyler, D. E., VanDeVoort, J. T., Kane, J. K., Ross, C. A., Raphael, D. E., Niedbalas, R. S., & Pentel, P. R. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37155-1 · Cited by 89 · see citing works
LeSage, M. G., Keyler, D. E., Hieda, Y., Collins, G., Burroughs, D., Le, C. T., & Pentel, P. R. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0027-2 · Cited by 74 · see citing works
A Computational Study of Nicotine Conformations in the Gas Phase and in Water
Elmore, D. E., & Dougherty, D. A. (2000) · The Journal of Organic Chemistry · doi:10.1021/jo991383q · Cited by 68 · see citing works
Enhanced immunogenicity of a bivalent nicotine vaccine
Keyler, D. E., Roiko, S. A., Earley, C. A., Murtaugh, M. P., & Pentel, P. R. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2008.07.001 · Cited by 68 · see citing works
Sanderson, S. D., Cheruku, S. R., Padmanilayam, M. P., Vennerstrom, J. L., Thiele, G. M., Palmatier, M. I., & Bevins, R. A. (2003) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00260-6 · Cited by 68 · see citing works
Preclinical Development of a Vaccine ‘Against Smoking’
Cerny, E. H., Levy, R., Mauël, J., Mpandi, M., Mutter, M., Henzelin-Nkubana, C., Patiny, L., Tuchscherer, G., & Cerny, T. (2002) · Oncology Research and Treatment · doi:10.1159/000067433 · Cited by 67 · see citing works
A New Strategy for Improved Nicotine Vaccines Using Conformationally Constrained Haptens
Meijler, M. M., Matsushita, M., Altobell, L. J., Wirsching, P., & Janda, K. D. (2003) · Journal of the American Chemical Society · doi:10.1021/ja034805t · Cited by 64 · see citing works
Duryee, M. J., Bevins, R. A., Reichel, C. M., Murray, J. E., Dong, Y., Thiele, G. M., & Sanderson, S. D. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.02.105 · Cited by 64 · see citing works
An Immunotherapeutic Program for the Treatment of Nicotine Addiction: Hapten Design and Synthesis
Isomura, S., Wirsching, P., & Janda, K. D. (2001) · The Journal of Organic Chemistry · doi:10.1021/jo001442w · Cited by 63 · see citing works
Cocaine catalytic antibodies: the primary importance of linker effects
Matsushita, M., Hoffman, T. Z., Ashley, J. A., Zhou, B., Wirsching, P., & Janda, K. D. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00659-4 · Cited by 60 · see citing works
Hyytiä, P., Schulteis, G., & Koob, G. F. (1996) · Psychopharmacology · doi:10.1007/bf02247335 · Cited by 50 · see citing works
Synthesis of carbamate-linked lipids for gene delivery
Liu, D., Hu, J., Qiao, W., Li, Z., Zhang, S., & Cheng, L. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.04.010 · Cited by 45 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Emerging Concepts and Technologies in Vaccine Development
Brisse, M. E., Vrba, S. M., Kirk, N. M., Liang, Y., & Ly, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583077 · Cited by 325 · see citing works
Phage display—A powerful technique for immunotherapy
Bazan, J., Całkosiński, I., & Gamian, A. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.21703 · Cited by 253 · see citing works
A Vaccine Strategy that Induces Protective Immunity against Heroin
Stowe, G. N., Vendruscolo, L. F., Edwards, S., Schlosburg, J. E., Misra, K., Schulteis, G., Mayorov, A. V., Zakhari, J. S., Koob, G. F., & Janda, K. D. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200461m · Cited by 116 · see citing works
Conjugate Vaccine Immunotherapy for Substance Use Disorder
Bremer, P. T., & Janda, K. D. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.013904 · Cited by 100 · see citing works
New Directions in Nicotine Vaccine Design and Use
Pentel, P. R., & LeSage, M. G. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-420118-7.00014-7 · Cited by 95 · see citing works
Injection Route and TLR9 Agonist Addition Significantly Impact Heroin Vaccine Efficacy
Bremer, P. T., Schlosburg, J. E., Lively, J. M., & Janda, K. D. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400631w · Cited by 85 · see citing works
Selection of a Novel Anti-Nicotine Vaccine: Influence of Antigen Design on Antibody Function in Mice
Pryde, D. C., Jones, L. H., Gervais, D. P., Stead, D. R., Blakemore, D. C., Selby, M. D., Brown, A. D., Coe, J. W., Badland, M., Beal, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076557 · Cited by 80 · see citing works
Nicotine Vaccines to Assist with Smoking Cessation
Raupach, T., Hoogsteder, P., & van Schayck, O. C. P. (2012) · Drugs · doi:10.2165/11599900-000000000-00000 · Cited by 74 · see citing works
Pharmacokinetic Strategies for Treatment of Drug Overdose and Addiction
Gorelick, D. A. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.11.190 · Cited by 73 · see citing works
Wee, S., Hicks, M. J., De, B. P., Rosenberg, J. B., Moreno, A. Y., Kaminsky, S. M., Janda, K. D., Crystal, R. G., & Koob, G. F. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.200 · Cited by 71 · see citing works
Adjuvants for vaccines to drugs of abuse and addiction
Alving, C. R., Matyas, G. R., Torres, O. B., Jalah, R., & Beck, Z. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.07.085 · Cited by 70 · see citing works
Mechanistic insights into nicotine withdrawal
Paolini, M., & De Biasi, M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.075 · Cited by 66 · see citing works
Hicks, M. J., De, B. P., Rosenberg, J. B., Davidson, J. T., Moreno, A. Y., Janda, K. D., Wee, S., Koob, G. F., Hackett, N. R., Kaminsky, S. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.280 · Cited by 63 · see citing works
Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration
George, O., Lloyd, A., Carroll, F. I., Damaj, M. I., & Koob, G. F. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2024-3 · Cited by 52 · see citing works
Xue, S., Schlosburg, J. E., & Janda, K. D. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b06605 · Cited by 51 · see citing works
Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food
Rüedi‐Bettschen, D., Wood, S. L., Gunnell, M. G., West, C. M., Pidaparthi, R. R., Carroll, F. I., Blough, B. E., & Owens, S. M. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.038 · Cited by 51 · see citing works
Pharmacokinetic Correlates of the Effects of a Heroin Vaccine on Heroin Self-Administration in Rats
Raleigh, M. D., Pentel, P. R., & LeSage, M. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115696 · Cited by 50 · see citing works
Kimishima, A., Wenthur, C. J., Zhou, B., & Janda, K. D. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00977 · Cited by 49 · see citing works
Investigating Hapten Clustering as a Strategy to Enhance Vaccines against Drugs of Abuse
Collins, K. C., & Janda, K. D. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500016k · Cited by 47 · see citing works
A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle
Hu, Y. Y., Zheng, H., Huang, W. C., & Zhang, C. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26635 · Cited by 47 · see citing works
Therapeutic and Prophylactic Vaccines to Counteract Fentanyl Use Disorders and Toxicity
Robinson, C., Gradinati, V., Hamid, F. A. A. A., Baehr, C., Crouse, B., Averick, S. E., Kovaliov, M., Harris, D. L., Runyon, S. P., Baruffaldi, F., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01042 · Cited by 47 · see citing works
AAV-Directed Persistent Expression of a Gene Encoding Anti-Nicotine Antibody for Smoking Cessation
Hicks, M. J., Rosenberg, J. B., De, B. P., Pagovich, O. E., Young, C. N., Qiu, J., Kaminsky, S. M., Hackett, N. R., Worgall, S., Janda, K. D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003611 · Cited by 47 · see citing works
Prophylactic vaccination protects against the development of oxycodone self-administration
Nguyen, J. D., Hwang, C. S., Grant, Y., Janda, K. D., & Taffe, M. A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.026 · Cited by 44 · see citing works
de Villiers, S. H. L., Cornish, K. E., Troska, A. J., Pravetoni, M., & Pentel, P. R. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.10.051 · Cited by 43 · see citing works
Developing a Vaccine Against Multiple Psychoactive Targets: A Case Study of Heroin
Stowe, G. N., Schlosburg, J. E., Vendruscolo, L. F., Edwards, S., Misra, K., Schulteis, G., Zakhari, J. S., Koob, G. F., & Janda, K. D. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711799219316 · Cited by 43 · see citing works
Vaccines targeting drugs of abuse: is the glass half-empty or half-full?
Janda, K. D., & Treweek, J. B. (2011) · Nature reviews. Immunology · doi:10.1038/nri3130 · Cited by 42 · see citing works
McCluskie, M. J., Thorn, J. M., Gervais, D. P., Stead, D. R., Zhang, N., Benoit, M., Cartier, J., Kim, I.-J., Bhattacharya, K., Finneman, J. I., et al. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.09.012 · Cited by 41 · see citing works
Phage display—A powerful technique for immunotherapy
Bazan, J., Całkosiński, I., & Gamian, A. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.21704 · Cited by 39 · see citing works
The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine
Hu, Y. Y., Smith, D., Frazier, E., Hoerle, R., Ehrich, M. F., & Zhang, C. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.08.028 · Cited by 38 · see citing works
A Conjugate Vaccine Using Enantiopure Hapten Imparts Superior Nicotine-Binding Capacity
Lockner, J. W., Lively, J. M., Collins, K. C., Vendruscolo, J. C. M., Azar, M. R., & Janda, K. D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501625j · Cited by 37 · see citing works
De, B. P., Pagovich, O. E., Hicks, M. J., Rosenberg, J. B., Moreno, A. Y., Janda, K. D., Koob, G. F., Worgall, S., Kaminsky, S. M., Sondhi, D., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.163 · Cited by 36 · see citing works
Enhancing nicotine vaccine immunogenicity with liposomes
Lockner, J. W., Ho, S. O., McCague, K. C., Chiang, S. M., Do, T. Q., Fujii, G., & Janda, K. D. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.12.048 · Cited by 36 · see citing works
Vaccines against drugs of abuse: where are we now?
Kinsey, B. M. (2014) · Therapeutic Advances in Vaccines · doi:10.1177/2051013614537818 · Cited by 34 · see citing works
Enzyme-Therapy Approaches for the Treatment of Drug Overdose and Addiction
Zheng, F., & Zhan, C. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.275 · Cited by 33 · see citing works
Hwang, C. S., Smith, L. C., Natori, Y., Ellis, B. A., Zhou, B., & Janda, K. D. (2018) · ACS Omega · doi:10.1021/acsomega.8b01478 · Cited by 31 · see citing works
Active vaccination attenuates the psychostimulant effects of α-PVP and MDPV in rats
Nguyen, J. D., Bremer, P. T., Ducime, A., Creehan, K. M., Kisby, B. R., Taffe, M. A., & Janda, K. D. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.12.005 · Cited by 25 · see citing works
Immunotherapies for the Treatment of Drug Addiction
Hossain, M. K., Davidson, M., Kypreos, E., Feehan, J., Muir, J. A., Nurgali, K., & Apostolopoulos, V. (2022) · Vaccines · doi:10.3390/vaccines10111778 · Cited by 23 · see citing works
Vaccine development against methamphetamine drug addiction
Hossain, M. K., Hassanzadeganroudsari, M., Nurgali, K., & Apostolopoulos, V. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1857738 · Cited by 23 · see citing works
Addiction and the adrenal cortex
Vinson, G. P., & Brennan, C. H. (2013) · Endocrine Connections · doi:10.1530/ec-13-0028 · Cited by 23 · see citing works
Suppression of Nicotine-Induced Pathophysiology by an Adenovirus Hexon-Based Antinicotine Vaccine
Rosenberg, J. B., De, B. P., Hicks, M. J., Janda, K. D., Kaminsky, S. M., Worgall, S., & Crystal, R. G. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.245 · Cited by 21 · see citing works
Probing the protective effects of a conformationally constrained nicotine vaccine
Moreno, A. Y., Azar, M. R., Koob, G. F., & Janda, K. D. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.08.064 · Cited by 21 · see citing works
Blake, S., Bremer, P. T., Zhou, B., Petrovsky, N., Smith, L. C., Hwang, C. S., & Janda, K. D. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00837 · Cited by 18 · see citing works
The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis
Martinez, S., Harris, H., Chao, T. W.-C., Luba, R. R., Pravetoni, M., Comer, S. D., & Jones, J. D. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2187286 · Cited by 17 · see citing works
Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models
Smith, L. C., & George, O. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108225 · Cited by 16 · see citing works
LeSage, M. G., Shelley, D., Pravetoni, M., & Pentel, P. R. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.03.026 · Cited by 16 · see citing works
Saylor, K., & Zhang, C. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.07.017 · Cited by 14 · see citing works
New medications development for smoking cessation
Lengel, D., & Kenny, P. J. (2023) · Addiction Neuroscience · doi:10.1016/j.addicn.2023.100103 · Cited by 12 · see citing works
Development and characterization of a novel conjugated methamphetamine vaccine
Hossain, M. K., Davidson, M., Feehan, J., Deraos, G., Nurgali, K., Matsoukas, J., & Apostolopoulos, V. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.043 · Cited by 11 · see citing works
Alzhrani, R. F., Xu, H., Valdes, S. A., & Cui, Z. (2020) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2020.1820033 · Cited by 10 · see citing works
Practical Considerations for the Development of Vaccines Against Drugs of Abuse
Torres, O. B., Alving, C. R., Jacobson, A. E., Rice, K. C., & Matyas, G. R. (2015) · Springer eBooks · doi:10.1007/978-3-319-23150-1_20 · Cited by 8 · see citing works
Bian, Y., Ci, Q., Luo, X., & Zhang, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091223 · Cited by 6 · see citing works
Evaluation of a hapten conjugate vaccine against the “zombie drug” xylazine
Lin, M., Eubanks, L. M., Zhou, B., & Janda, K. D. (2024) · Chemical Communications · doi:10.1039/d4cc00883a · Cited by 5 · see citing works
Yan, K., Xu, S., Fang, H., Yang, H., & Su, D. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127036 · Cited by 4 · see citing works
A methamphetamine vaccine using short monoamine and diamine peptide linkers and poly-mannose
Hossain, M. K., Davidson, M., Feehan, J., Matsoukas, J., Nurgali, K., & Apostolopoulos, V. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117930 · Cited by 4 · see citing works
Emerging Neurobiological Treatments of Addiction
Carter, A., Capps, B., & Hall, W. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-385973-0.00005-3 · Cited by 4 · see citing works
Bhatt, L. K. (2025) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-025-01336-0 · Cited by 3 · see citing works
Hapten Design for Anti-addiction Vaccine Development
Collins, K. C., & Janda, K. D. (2015) · Springer eBooks · doi:10.1007/978-3-319-23150-1_18 · Cited by 2 · see citing works
Ethical Issues in the Treatment of Addiction
Capps, B., Carter, A., & van der Eijk, Y. (2014) · Springer eBooks · doi:10.1007/978-94-007-4707-4_70 · Cited by 2 · see citing works
[Recent progress in vaccines against nicotine addiction].
Wang, G., & Zhu, C.-J. (2013) · PubMed · Cited by 2 · see citing works
Foreword: The Neuroethics of Drug Addiction
Robbins, T. W. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-385973-0.00020-x · Cited by 2 · see citing works
Collins, B. N., & Nair, U. S. (2013) · Wiley eBooks · doi:10.1002/9781394260454.ch6 · Cited by 2 · see citing works
Goutal, S., Tran, T., Leroy, C., Benhamouda, N., Leterrier, S., Saba, W., Lafont, B., Tartour, É., Roelens, M., & Tournier, N. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00204 · Cited by 1 · see citing works
Méndez, S. B., & Salazar‐Juárez, A. (2025) · Brain Sciences · doi:10.3390/brainsci15040364 · Cited by 1 · see citing works
Adenovirus-Based Vaccines for the Treatment of Substance Use Disorders
Havlicek, D. F., Rosenberg, J. B., Sondhi, D., Crystal, R. G., & Kaminsky, S. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-23150-1_13 · Cited by 1 · see citing works
Therapeutic Vaccines for Treating Nicotine Addiction
Kalnik, M. W. (2015) · Springer eBooks · doi:10.1007/978-3-319-23150-1_2 · Cited by 1 · see citing works
Prophylactic vaccination protects against the development of oxycodone self-administrationPreprint
Nguyen, J. D., Hwang, C. S., Grant, Y., Janda, K. D., & Taffe, M. A. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/210369 · Cited by 1 · see citing works
Enhancing the efficacy of a nicotine vaccine
Cornish, K. E. (2013) · University of Minnesota Digital Conservancy (University of Minnesota)
Vaccination against nicotine to facilitate smoking cessation
Raupach, T. (2013) · doi:10.2217/ebo.12.204
Estado actual de las vacunas contra la nicotina: una revisión narrativa
Méndez, S. B., & Salazar‐Juárez, A. (2018) · Vacunas · doi:10.1016/j.vacun.2018.09.004
Characterization and Engineering of Human Proteins as Therapeutic Candidates
Kim, K. (2018) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2018.354
David, S. P., McClure, J. B., & Swan, G. E. (2012) · Wiley eBooks · doi:10.1002/9781118133880.hop209007
Current status of nicotine vaccines: A narrative review
Méndez, S. B., & Salazar‐Juárez, A. (2018) · Vacunas (English Edition) · doi:10.1016/j.vacune.2018.09.001
Synthesis of Drug Vaccine against Heroin Contaminated with Fentanyl and Their Biological Evaluation
Natori, Y., & Janda, K. D. (2020) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.78.875
- Authors
- Moreno, A. Y., Azar, M. R., Warren, N. A., Dickerson, T. J., Koob, G. F., & Janda, K. D.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Janda, Kim D.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2010-02-08
- Volume
- 7
- Issue
- 2
- Pages
- 431-441
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W1989900278
- Cited by
- 73
- References
- 26
- Citations by year
- 2025: 4 · 2024: 3 · 2023: 2 · 2022: 2 · 2020: 7 · 2018: 5 · 2017: 2 · 2016: 4 · 2015: 6 · 2014: 8 · 2013: 10 · 2012: 10
- FWCI
- 6.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- nicotine vaccine, nicotine dependence, tobacco smoking cessation, immunopharmacotherapy, self-administration, hapten conjugation, adjuvants
- MeSH terms
- Animals, Antibodies, Enzyme-Linked Immunosorbent Assay, Infusions, Intravenous, Male, Models, Theoretical, Nicotine, Tobacco Use Disorder, Vaccines, Immunoconjugates, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
